Markson, Victor I.
January 1964
Angiology;Jan1964, Vol. 15 Issue 1, p51
Academic Journal
1. The use of anticoagulant therapy for patients with thromboembolic disease on an outpatient basis is recorded for 144 cases followed from 3 months to 5 years using, as the anticoagulant of choice, warfarin sodium. 2. Safe, therapeutic prothrombin levels can be reached and maintained satisfactorily in a majority of cases. 3. Clinical improvement over previously accepted standards of care has been striking. 4. No serious side effects or hemorrhages were encountered, particularly after vitamin C was administered in conjunction with warfarin sodium.


Related Articles

  • The relationship between CYP2C9 gene polymorphisms and upper gastrointestinal bleeding in patients who used warfarin. Ucar, Mahmut; Alagozlu, Hakan; Sahin, Safak; Ozdemir, Ozturk // Medicinski Glasnik;Feb2013, Vol. 10 Issue 1, p50 

    Aim Oral anticoagulants are the most common used substance for treatment and prophylaxis of warfarin venous and arterial thromboembolic disorders in the world. Therapeutic index of warfarin is narrow. CYP2C9 is a hepatic microsomal enzyme and has a primary role in metabolism of warfarin and...

  • Anticoagulation without monitoring? Elliott, William T. // Infectious Disease Alert;Feb2010 Supplement, p1 

    The article presents the findings of a study about dabigatran, an oral direct thrombin inhibitor which serves as an alternative to warfarin. It references a study published in the December 2009 issue of "New England Journal of Medicine." Results showed that 2.4% of the patients randomized to...

  • INITIATING WARFARIN TREATMENT. Schooff, Michael // Journal of Family Practice;Apr1999, Vol. 48 Issue 4, p250 

    The article cites a research study that analyzes whether it is better to initiate warfarin therapy with a 5-mg or a 10-mg dose. Initiation of warfarin therapy usually takes 4 to 5 days, until a therapeutic international normalized ratio (INR) has been maintained for 2 consecutive days. Various...

  • The Risks of Thromboembolism Vs. Recurrent Gastrointestinal Bleeding after Interruption of Systemic Anticoagulation in Hospitalized Inpatients With Gastrointestinal Bleeding: A Prospective Study. Sengupta, N; Feuerstein, J D; Patwardhan, V R; Tapper, E B; Ketwaroo, G A; Thaker, A M; Leffler, D A // American Journal of Gastroenterology;Feb2015, Vol. 110 Issue 2, p328 

    OBJECTIVES:Anticoagulants carry a significant risk of gastrointestinal bleeding (GIB). Data regarding the safety of anticoagulation continuation/cessation after GIB are limited. We sought to determine the safety and risk of continuation of anticoagulation after GIB.METHODS:We conducted a...

  • Suprachoroidal haemorrhage after addition of clarithromycin to warfarin. Dandekar, S. S.; Laidlaw, D. A. H. // Journal of the Royal Society of Medicine;Nov2001, Vol. 94 Issue 11, p583 

    The article focuses on the case of a 62-year-old woman who developed a suprachoroidal hemorrhage after addition of clarithromycin to her warfarin medication. It is indicated that the patient, who has chronic atrial fibrillation, lost anticoagulant control due to the interaction between the two...

  • ORAL ANTICOAGULATION. Alexander, Christine; Rana, Sangeeta // Journal of Family Practice;Jan1996, Vol. 42 Issue 1, p21 

    This article presents information on the optimal intensity of oral anticoagulant theory concerning the preventative measures associated with thromboembolic complications. Patients with mechanical heart valves require lifelong high-intensity oral anticoagulation to prevent thromboembolic...

  • Identifying the Risks of Anticoagulation in Patients with Substance Abuse. Efird, Lydia; Miller, Donald; Ash, Arlene; Berlowitz, Dan; Ozonoff, Al; Zhao, Shibei; Reisman, Joel; Jasuja, Guneet; Rose, Adam // JGIM: Journal of General Internal Medicine;Oct2013, Vol. 28 Issue 10, p1333 

    BACKGROUND: Warfarin is effective in preventing thromboembolic events, but concerns exist regarding its use in patients with substance abuse. OBJECTIVE: Identify which patients with substance abuse who receive warfarin are at risk for poor outcomes. DESIGN: Retrospective cohort study. Diagnostic...

  • Kontrolsüz Warfarin Kullanımına BaÄŸlı GeliÅŸen Yaygın Alveoler Hemoraji: Olgu Sunumu. Akagün, Tülin; Güngör, Erdal; Akdogan, Elif; Bülbül, Yilmaz; Sönmez, Mehmet // International Journal of Hematology & Oncology / UHOD: Uluslarar;Sep2008, Vol. 18 Issue 3, p170 

    Warfarin; one of the most common oral anticoagülant drug is used for treatment of thromboembolic events and also for prevention of thromboembolic complications in atrial fibrillation and other cardiovascular diseases. The most important adverse effect is hemorrhage. Diffuse alveolar...

  • Warfarin.  // Reactions Weekly;6/1/2013, Issue 1455, p34 

    The article describes the case of a 68-year-old man who developed a perirenal haemorrhage while receiving treatment with anticoagulation and warfarin.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics